Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25257
Title: DNA methylation profiling identifies epigenetic differences between early versus late stages of diabetic chronic kidney disease.
Austin Authors: Lecamwasam, Ashani ;Novakovic, Boris;Meyer, Braydon;Ekinci, Elif I ;Dwyer, Karen M;Saffery, Richard
Affiliation: Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
Endocrinology
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Epigenetics Research, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
School of Medicine, Faculty of Health, Deakin University, Melbourne, Victoria, Australia
Issue Date: 2021
Date: 2020
Publication information: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association 2021; 36(11): 2027-2038
Abstract: We investigated a cross-sectional epigenome-wide association study of patients with early and late diabetes-associated chronic kidney disease (CKD) to identify possible epigenetic differences between the two groups as well as changes in methylation across all stages of diabetic CKD. We also evaluated the potential of using a panel of identified 5'-C-phosphate-G-3' (CpG) sites from this cohort to predict the progression of diabetic CKD. This cross-sectional study recruited 119 adults. DNA was extracted from blood using the Qiagen QIAampDNA Mini Spin Kit. Genome-wide methylation analysis was performed using Illumina Infinium MethylationEPIC BeadChips (HM850K). Intensity data files were processed and analysed using the minfi and MissMethyl packages for R. We examined the degree of methylation of CpG sites in early versus late diabetic CKD patients for CpG sites with an unadjusted P-value <0.01 and an absolute change in methylation of 5% (n = 239 CpG sites). Hierarchical clustering of the 239 CpG sites largely separated the two groups. A heat map for all 239 CpG sites demonstrated distinct methylation patterns in the early versus late groups, with CpG sites showing evidence of progressive change. Based on our differentially methylated region (DMR) analysis of the 239 CpG sites, we highlighted two DMRs, namely the cysteine-rich secretory protein 2 (CRISP2) and piwi-like RNA-mediated gene silencing 1 (PIWIL1) genes. The best predictability for the two groups involved a receiver operating characteristics curve of eight CpG sites alone and achieved an area under the curve of 0.976. We have identified distinct DNA methylation patterns between early and late diabetic CKD patients as well as demonstrated novel findings of potential progressive methylation changes across all stages (1-5) of diabetic CKD at specific CpG sites. We have also identified associated genes CRISP2 and PIWIL1, which may have the potential to act as stage-specific diabetes-associated CKD markers, and showed that the use of a panel of eight identified CpG sites alone helps to increase the predictability for the two groups.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25257
DOI: 10.1093/ndt/gfaa226
ORCID: 0000-0003-2372-395X
Journal: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
PubMed URL: 33146725
Type: Journal Article
Subjects: DNA methylation
chronic kidney disease
diabetes
epigenetics
Appears in Collections:Journal articles

Show full item record

Page view(s)

42
checked on Apr 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.